In collaboration with the British Toxicology Society (BTS), the NC3Rs is hosting a virtual workshop on 15 September 2022. The session will be chaired by Dr David Jones, independent consultant (previously senior reviewer at Medicines and Healthcare products Regulatory Agency). This is a ‘re-run’ of a session presented during the 2022 BTS congress, to allow global participation and further discussion.
A microsample is typically defined as a sample of blood that is ≤50 μl. Adoption of this technique can reduce or avoid the use of satellite animals for toxicokinetics or other purposes and also provides refinements applicable for both rodents and larger animals. Microsampling can increase the scientific value of data obtained from rodent studies during drug and chemical discovery and development, enabling multiple endpoints to be investigated and compared in the same animal.
Since 2011, the NC3Rs has promoted the 3Rs, scientific and business benefits to microsampling, guided by an expert working group. Investigations were recently initiated to understand the current use of microsampling in toxicology studies across pharmaceutical, agrochemical and academia sectors, with the aim of identifying the specific studies in which microsampling is employed and the barriers to wider uptake.
The symposium aims to raise awareness of the microsampling technique and encourage wider adoption across both discovery and regulatory toxicology studies.
Key objectives are to:
- Showcase how microsampling is currently being used within pharmaceutical and agrochemical safety assessment toxicology studies, within different species and study types.
- Highlight the current barriers and concerns that if addressed could encourage the adoption of microsampling for more studies, providing reduction and refinements in animal use.
- Provide real-life examples of how companies are successfully using microsampling, and future directions.
This webinar will be relevant for all academic, regulatory and industry scientists interested in applying the 3Rs in rodent and non-rodent studies. There will be a panel discussion at the end of the webinar, with an opportunity for audience members to ask questions.
The draft agenda for the workshop is below:
Welcome and introductions
Dr David Jones, Independent consultant (CHAIR)
Preclinical to clinical use of microsamples – start small, stay small
Dr Neil Spooner, Spooner Bioanalytical Solutions Ltd
|14.20 - 14.35||
Current use, 3Rs benefits and barriers for microsampling: results from a 2021 cross-sector survey
Dr Helen Prior, NC3Rs
|14.35 - 14.50||
Leveraging experience from small molecule microsampling towards large molecules and other drug modalities
Dr Amanda Wilson, AstraZeneca
|14.50 - 15.05||
Incorporating microsampling for agrochemical TK data to improve risk assessment
Dr Derek Angus, Syngenta
|15.05 - 15.20||
Microsampling of main test animals without detriment to clinical pathology parameters
Carol Strepka, Charles River Laboratories Edinburgh
|15.20 - 15.35||
Animal welfare benefits of microsampling for any purpose
Dr Hollie Blunt, Sequani
|15.35 - 16.00||
Panel discussion / Q&As